Nutritional Strategies for Managing Gastrointestinal Adverse Effects Associated with GLP-1 Receptor Agonist and Dual GIP/GLP-1 Receptor Agonist Therapy: A Narrative Review with Practical Recommendations

Incretin-based therapies have marked a turning point in the treatment of obesity, because of their demonstrated effects on body weight and beyond, including numerous cardi-ometabolic outcomes. Within obesity management, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GIP/GLP-1 RAs) are, to date, the most effective pharma-cological strategies. A growing body of evidence, however, points to limited tolerability caused by gastrointestinal adverse effects, which may impair treatment adherence and reduce both quality of life and the nutritional adequacy of patients’ diets. These effects, which include nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal bloating, are often observed in the early phases of treatment and during dose escalation. Yet the dietary recommendations available for their management remain fragmentary and inaccurate. This narrative review sets out to analyze the main pathophysiological mechanisms un-derlying the gastrointestinal manifestations of incretin-based therapies and to gather the available evidence on nutritional strategies for their prevention and management. We address the contribution of the GLP-1 and GIP systems to the modulation of gastroin-testinal motility, appetite, and clinical tolerability, with attention to the differences cur-rently recognized between selective GLP-1 RAs and dual GIP/GLP-1 RAs. We then present practical, symptom-specific recommendations covering meal distribution, mod-ulation of fat and fiber intake, hydration, food choices, and the overall quality of diet and lifestyle. Finally, we discuss the key role of nutrition in preservation adequate energy and protein intake, preventing micronutrient deficiencies, and conserving muscle mass throughout treatment with incretin-based therapies. A structured, personalized, symptom-oriented nutritional approach could improve the tolerability of these therapies, optimize clinical outcomes, and support their efficacy over the long term.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-13
DOI
https://doi.org/10.20944/preprints202611.1418.v1
Primary Topic
Pharmacology and Obesity Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Nutritional Strategies for Managing Gastrointestinal Adverse Effects Associated with GLP-1 Receptor Agonist and Dual GIP/GLP-1 Receptor Agonist Therapy: A Narrative Review with Practical Recommendations

Antonio Cilona, Maurizio Li Vecchi, Luca Elli, Alessandra Dell’Era et al.
8 links
Preprints.org
Pharmacology and Obesity Treatment
preprint

Nutritional Strategies for Managing Gastrointestinal Adverse Effects Associated with GLP-1 Receptor Agonist and Dual GIP/GLP-1 Receptor Agonist Therapy: A Narrative Review with Practical Recommendations

Antonio Cilona, Maurizio Li Vecchi, Luca Elli, Alessandra Dell’Era, Andrea Costantino, Carlo Tommaso, Felice Cinque, Alice Scricciolo, Flavio Caprioli, Federica Mascaretti, Vincenza Lombardo, Leda Roncoroni, Beatrice Rota, Nicola Siragusa, Lorenzo Ferrario, Gloria Baldassari, Laura Passera, Luca Pozzi, Ruggero Davide Romano
preprint en

Abstract

Incretin-based therapies have marked a turning point in the treatment of obesity, because of their demonstrated effects on body weight and beyond, including numerous cardi-ometabolic outcomes. Within obesity management, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GIP/GLP-1 RAs) are, to date, the most effective pharma-cological strategies. A growing body of evidence, however, points to limited tolerability caused by gastrointestinal adverse effects, which may impair treatment adherence and reduce both quality of life and the nutritional adequacy of patients’ diets. These effects, which include nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal bloating, are often observed in the early phases of treatment and during dose escalation. Yet the dietary recommendations available for their management remain fragmentary and inaccurate. This narrative review sets out to analyze the main pathophysiological mechanisms un-derlying the gastrointestinal manifestations of incretin-based therapies and to gather the available evidence on nutritional strategies for their prevention and management. We address the contribution of the GLP-1 and GIP systems to the modulation of gastroin-testinal motility, appetite, and clinical tolerability, with attention to the differences cur-rently recognized between selective GLP-1 RAs and dual GIP/GLP-1 RAs. We then present practical, symptom-specific recommendations covering meal distribution, mod-ulation of fat and fiber intake, hydration, food choices, and the overall quality of diet and lifestyle. Finally, we discuss the key role of nutrition in preservation adequate energy and protein intake, preventing micronutrient deficiencies, and conserving muscle mass throughout treatment with incretin-based therapies. A structured, personalized, symptom-oriented nutritional approach could improve the tolerability of these therapies, optimize clinical outcomes, and support their efficacy over the long term.

Preprints.org
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon